Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Therapeutics Inc. director Paul J. Hastings received a grant of stock options for 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Michael Thomas Heffernan reported receiving a stock option grant covering 31,000 Common Shares. The option has an exercise price of $1.75 per share, giving him the right to buy shares at that price in the future.
The option was granted as a compensation award and expires on June 16, 2036. It vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Wouter Joustra received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. According to the footnote, the option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders.
enGene Therapeutics Inc. director Lota S. Zoth reported receiving a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
According to the terms, the entire option award vests on the earlier of the first anniversary of the vesting commencement date of June 9, 2026 or the company’s 2027 annual meeting of shareholders. After this grant, Zoth holds 31,000 stock options directly.
enGene Therapeutics reported a net loss of $30.2M for the quarter and $60.0M for the six months ended April 30, 2026, driven by research and development and growing general and administrative costs. Operating cash outflow was $59.4M over six months.
The company held $29.8M in cash and cash equivalents and $255.2M in marketable securities, with total assets of $307.5M and shareholders’ equity of $255.2M. Management expects this liquidity to fund operations and debt obligations for at least 12 months, but anticipates needing additional capital thereafter.
enGene expanded its debt facility to up to $125M, drawing $25M, and raised equity through a late-2025 public offering and pre-funded warrants. Subsequent to quarter-end, it announced a workforce reduction of about 50% and a strategic restructuring to preserve cash while advancing its LEGEND trial of detalimogene and preparing for a potential BLA filing.
enGene Therapeutics reported a Q2 2026 net loss of $30.2 million, or $0.43 per share, as total operating expenses rose to $32.0 million from $27.1 million a year earlier, driven by higher research, clinical and administrative costs.
Cash, cash equivalents and marketable securities were $285.2 million as of April 30, 2026, supporting ongoing development of detalimogene. Interim data from the LEGEND pivotal Cohort 1 showed a 54% complete response rate (67/124 patients) with a 3.2% progression rate in high-risk BCG‑unresponsive NMIBC.
The company is implementing a strategic restructuring, including an approximately 50% workforce reduction, with estimated restructuring costs of $5.7–$6.4 million plus $4.7–$5.0 million in non‑cash stock‑based compensation. Several senior executives, including the CFO, CMO, CLO and CSO, are departing, while new finance leadership and an interim CMO have been appointed.
enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.
Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”
enGene Holdings Inc. filed an Amendment No. 1 Schedule 13G/A reporting that Cormorant Asset Management, LP and Bihua Chen hold 0 shares of Common Stock, representing 0% of the class. The filing cites 66,989,466 shares outstanding as of March 3, 2026.
The statement clarifies the reporting persons act as investment adviser to certain funds and that the filing should not be construed as an admission of beneficial ownership under Section 13. The signature date shown is May 15, 2026.
BML Investment Partners, L.P. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 6,669,908 common shares of enGene Holdings Inc. The filing states these shares represent 9.95% of the class as of the report and lists shared voting and shared dispositive power over those shares. The filing identifies the reporting person as BML Investment Partners, L.P. (a Delaware limited partnership) and discloses that BML Capital Management, LLC and Braden M. Leonard are indirect owners/agents with signature dated 05/14/2026.
enGene Holdings Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 5,225,000 common shares, representing 7.8% of the class as shown on 05/08/2026. The filing states shared voting and dispositive power over these shares through BML Capital Management, LLC and Braden M. Leonard.